JPS6130509A - Dermal external drug - Google Patents

Dermal external drug

Info

Publication number
JPS6130509A
JPS6130509A JP15258184A JP15258184A JPS6130509A JP S6130509 A JPS6130509 A JP S6130509A JP 15258184 A JP15258184 A JP 15258184A JP 15258184 A JP15258184 A JP 15258184A JP S6130509 A JPS6130509 A JP S6130509A
Authority
JP
Japan
Prior art keywords
urea
amino acid
basic amino
external drug
acid salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP15258184A
Other languages
Japanese (ja)
Inventor
Takeshi Yanagida
威 柳田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shiseido Co Ltd
Original Assignee
Shiseido Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiseido Co Ltd filed Critical Shiseido Co Ltd
Priority to JP15258184A priority Critical patent/JPS6130509A/en
Publication of JPS6130509A publication Critical patent/JPS6130509A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42Amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/007Preparations for dry skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

PURPOSE:A dermal external drug, containing urea and further a basic amino acid salt together, capable of improving the stability of the urea in the presence of water with time, and useful for cosmetics or medicines, e.g. a remedy for xeroderma. CONSTITUTION:A dermal external drug, obtained by incorporating a basic amino acid salt, e.g. hydrochloride, hydrobromide, acetate, pyrrolidonecarboxylate or urocanate of a basic amino acid, e.g. histidine, lysine, ornithine or arginine, etc. in an amount of 1/10-3 times that of urea in a dermal external drug containing 0.1-2wt% urea having wetting effect, cell activating effect and wound curing effect, etc., and capable of suppressing the decomposition of the urea in the presence of water and preventing the deterioration of the dermal external drug and pH increase, and having improved stability with time.

Description

【発明の詳細な説明】 [産業上の利用分野] 本発明は尿素と共に塩基性アミノ酸塩を配合することに
より、尿素の経口安定性を向上させた皮膚外用剤に関す
るものである。
DETAILED DESCRIPTION OF THE INVENTION [Industrial Application Field] The present invention relates to a skin preparation for external use that improves the oral stability of urea by incorporating a basic amino acid salt with urea.

[従来の技術] 尿素は皮膚外用剤中に配合した場合、湿潤効果、細胞賦
活効果、創傷治癒効果等が期待される。しかしながら水
の共存下で徐々に分解しアンモニア及び炭酸ガスを発生
するために、種々の効果が期待されつつも化粧料に配合
される機会がすくなかった。
[Prior Art] When urea is incorporated into external skin preparations, it is expected to have moisturizing effects, cell activation effects, wound healing effects, and the like. However, because it gradually decomposes in the presence of water and generates ammonia and carbon dioxide gas, there have been few opportunities to incorporate it into cosmetics, although it is expected to have various effects.

尿素を安定に皮膚外用剤に配合する努力はいくつか報告
があるが、そのいずれもが満足のいく結果を得ていなる
)。
There have been several reports of efforts to stably incorporate urea into external preparations for the skin, but none of them have yielded satisfactory results).

例えば、尿素とともに乳酸を配合する報告< usp3
666863号)では初期pIlが低下できるものの経
口安定性向上には効果がない。
For example, a report on combining lactic acid with urea < usp3
No. 666863) can reduce the initial pIl but is not effective in improving oral stability.

[発明が解決しようとする問題点] 本発明者らはかかる事情にかんがみ、水の共存下におけ
る尿素の経口安定性を向上させるべく鋭意検討を行った
結果、本発明をなすに至った。
[Problems to be Solved by the Invention] In view of the above circumstances, the present inventors conducted intensive studies to improve the oral stability of urea in the coexistence of water, and as a result, they came up with the present invention.

[問題点を解決するための手段] すなわち本発明は尿素と塩基性アミノ酸塩とを配合する
ことを特徴とする皮膚外用剤を提供するものである。
[Means for Solving the Problems] That is, the present invention provides an external skin preparation characterized by blending urea and a basic amino acid salt.

以下本発明の構成について詳述する。The configuration of the present invention will be explained in detail below.

本発明で用いられる尿素としては通常市販されているも
ので構わない。
As the urea used in the present invention, any commercially available urea may be used.

尿素の配合量は0.1〜20重量%(以下、単に%と称
す)の範囲で、それ以下の水準では前述の尿素の皮膚に
対する効果が少なく、またそれ以上の水準は薬事法上、
皮膚外用剤の範囲を逸脱するものであり規制を受ける。
The blending amount of urea is in the range of 0.1 to 20% by weight (hereinafter simply referred to as %); below that level, the above-mentioned effect of urea on the skin is small, and above that level, according to the Pharmaceutical Affairs Law.
This is outside the scope of external skin preparations and is subject to regulations.

安定性を向上させる目的で配合される塩基性アミノ酸塩
を構成する塩基性アミノ酸としてはヒスチジン、リジン
、オルニチン、アルギニンなどがあり、塩としては塩酸
塩、臭化水素酸塩をはじめ酢酸塩、ピロリドンカルボン
酸塩、ウロカニン酸塩などの有機酸塩も用いることがで
きる。
The basic amino acids that make up the basic amino acid salts added for the purpose of improving stability include histidine, lysine, ornithine, and arginine, and the salts include hydrochloride, hydrobromide, acetate, and pyrrolidone. Organic acid salts such as carboxylates and urocanates can also be used.

塩基性アミノ酸塩の配合量は尿素に対して重量で1/1
0倍以上3倍以下が望ましい。ただし過剰の塩基性アミ
ノ酸塩の添加は塩基性アミノ酸塩自身が変質し、変色、
変臭等を生じるために注意が必要である。
The amount of basic amino acid salt added is 1/1 by weight of urea.
It is desirable that it is 0 times or more and 3 times or less. However, adding too much basic amino acid salt may cause the basic amino acid salt itself to change in quality, causing discoloration and
Care must be taken as it may cause off-odor, etc.

尿素および塩基性アミノ酸塩を配合できる皮膚外用剤基
剤は通常考えられる皮膚外用剤基剤、例えば、可溶化系
、乳化系、粉末分散系、水−泊系2層状化粧料、水−油
一粉末系3N状化粧料等どのような基剤でもよく、用途
も化粧水、乳液、クリーム、パック等の基礎化粧料、乳
化口紅、ファウンディション等のメイクアップ化粧料、
シャンプー、リンス、ヘアトニック等の頭髪化粧料等の
化粧料のほかに乾皮症治療薬などの医薬品等多岐に亘る
が、本発明の効果は、尿素水溶液の形で含まれているも
のにおいて発揮される。尿素水溶液の濃度は任意である
。また、上述のように尿素水溶液が油相と乳化された形
等になっていても全く差し支えなく本発明の効果は発揮
される。しかしながら、基剤自身が強い塩基性を示すも
のについては塩基性アミノ酸塩による安定性維持効果以
上に塩基性物質による分解促進の方が大きい場合があり
、好ましくない。
The skin external preparation bases that can contain urea and basic amino acid salts include the usual skin external preparation bases, such as solubilized systems, emulsified systems, powder dispersion systems, water-based two-layer cosmetics, and water-oil based cosmetics. Any base such as powder type 3N cosmetics can be used, and the application is basic cosmetics such as lotion, milky lotion, cream, pack, etc., makeup cosmetics such as emulsified lipstick, foundation, etc.
In addition to cosmetics such as hair cosmetics such as shampoos, conditioners, and hair tonics, there is a wide range of pharmaceutical products such as drugs for treating xeroderma. be done. The concentration of the urea aqueous solution is arbitrary. Further, as described above, even if the urea aqueous solution is in an emulsified form with an oil phase, there is no problem and the effects of the present invention can be exhibited. However, if the base itself is strongly basic, the basic substance may promote decomposition more than the stability maintaining effect of the basic amino acid salt, which is not preferable.

本発明の皮膚外用剤には必要に応じて、本発明の効果を
損なわない範囲で保湿剤、増粘剤、防腐剤、乳化剤、酸
化防止剤、金属イオン封鎖剤、紫外線吸収剤、粉末、薬
効成分、色剤、香料等を配合できる。
The skin external preparation of the present invention may contain moisturizers, thickeners, preservatives, emulsifiers, antioxidants, sequestrants, ultraviolet absorbers, powders, medicinal agents, etc., as necessary, to the extent that the effects of the present invention are not impaired. Ingredients, colorants, fragrances, etc. can be added.

本発明に従って皮膚外用剤中に尿素と塩基性アミノ酸塩
とを同時に配合した場合の尿素の経口安定性は、塩基性
アミノ酸塩を併用しない場合に比較して著しく向上する
。すなわち、(イ)尿素の分解によるアンモニアの発生
がおこらず、アンモニア臭による皮膚外用剤の劣化がな
い。(ロ)塩基性アミノ酸塩を併用しない系ではpH値
が急激に上昇するが、併用した場合にはpH上昇がほと
んどおこらない等の効果が認められる。
According to the present invention, when urea and a basic amino acid salt are simultaneously incorporated into a skin preparation for external use, the oral stability of urea is significantly improved compared to when the basic amino acid salt is not used in combination. That is, (a) ammonia is not generated due to decomposition of urea, and the skin external preparation does not deteriorate due to ammonia odor. (b) In a system in which a basic amino acid salt is not used in combination, the pH value rises rapidly, but when used in combination, effects such as almost no pH rise are observed.

[実施例および発明の効果] つぎに本発明を実施例および比較例によりさらに詳細に
説明するが、本発明はこれにより限定されるものではな
い。
[Examples and Effects of the Invention] Next, the present invention will be explained in more detail with reference to Examples and Comparative Examples, but the present invention is not limited thereto.

実施例1〜2、比較例1〜3 (以下余白) 基剤=化粧水 エタノール               13.0%
1.3−ブチレングリコール        10.O
P、O,E、 (50)オレイルエーテル     0
.8防腐剤                適量香料
                 適量上記各基剤成
分と尿素および添加剤を加え、さらに全量を100とす
る量の精製水を加える。
Examples 1-2, Comparative Examples 1-3 (blank below) Base = lotion ethanol 13.0%
1.3-Butylene glycol 10. O
P, O, E, (50) Oleyl ether 0
.. 8 Add preservatives, appropriate amounts of fragrances, appropriate amounts of each of the above base components, urea, and additives, and then add purified water in an amount to make the total amount 100%.

は塩基性アミノ酸塩以外の添加剤を配合した試料である
is a sample containing additives other than basic amino acid salt.

pH変化、アンモニア臭、匂い変化共に少ない方が望ま
しく、定量は高い方が望ましいわけであるが、実施例に
おいてはこのいずれをも満足している。
It is desirable that the pH change, ammonia odor, and odor change are both small, and that the quantitative value is high, and the examples satisfy all of these.

実施例3 ナイトクリーム A、セフノール             4.0%ワ
セリン              7.0スクワラン
            21.0ステアリン酸モノグ
リセリン     2.2エステル P、0.E、 (20)ソルビタン       2.
8モノステアレート イソプロビルミリステート      6.0エチルバ
ラヘン           0.3香料      
          0.2B、グリセリン     
      10.0プロピレングリコール     
  5.0尿素                10
.OL−アルギニン塩酸塩        3.0精製
水       全体を100とする量Aに属する油相
部の原料およびBに属する水相部の原料をそれぞれ70
℃に加熱し完全熔解したのち、油相部を水相部中に混合
し、乳化機にて乳化する。乳化物を熱交換機にて終湯3
0℃まで冷却してナイトクリームを得た。
Example 3 Night cream A, Cefnol 4.0% Vaseline 7.0 Squalane 21.0 Monoglyceryl stearate 2.2 Ester P, 0. E, (20) Sorbitan 2.
8 Monostearate Isoprobyl myristate 6.0 Ethylvarachen 0.3 Fragrance
0.2B, glycerin
10.0 Propylene glycol
5.0 Urea 10
.. OL-Arginine Hydrochloride 3.0 Purified Water 70% each of the raw material for the oil phase belonging to A and the raw material for the aqueous phase belonging to B, with the total amount being 100.
After heating to ℃ and completely melting, the oil phase is mixed into the water phase and emulsified using an emulsifying machine. Finish the emulsion with a heat exchanger 3
A night cream was obtained by cooling to 0°C.

実施例3に記載された処方からし一アルギニン塩酸塩の
みを除去した処方を実施例3と同時に調整し、40℃に
て2ケ月保存したのち尿素の定量をおこなったところ、
実施例3では98〜99%残存していたのに対し、L−
アルギニン塩酸塩を除去したものは87〜89%に減少
していた。
The formulation described in Example 3, in which only mustard monoarginine hydrochloride was removed, was prepared at the same time as Example 3, and after being stored at 40°C for 2 months, urea was quantified.
In Example 3, 98-99% remained, whereas L-
When arginine hydrochloride was removed, the amount decreased to 87-89%.

実施例4 ファンデーション A、セフノール             3.5%説
臭ラノリン           4.0ボホバ油  
            5.0ワセリン      
        2.0スクワラン         
   6.0ステアリン酸モノグリセリン     2
.5エステル P、O,E  (60)硬化ヒマシ油      1.
5P、0.E  (25)セチルエーテル    1.
0プロピルパラベン          0.3香料 
               0.2B、グリセリン
           3.0プロピレングリコール 
      8.0調合粉末            
 12.0尿素                3.
OL−オルニチン塩酸塩       2.0精製水 
      全体を100とする量実施例3に準じてフ
ァンデーションを得た。
Example 4 Foundation A, Cefnol 3.5% odor lanolin 4.0 Bojoba oil
5.0 Vaseline
2.0 squalane
6.0 Monoglyceryl stearate 2
.. 5 esters P, O, E (60) Hydrogenated castor oil 1.
5P, 0. E (25) Cetyl ether 1.
0 Propylparaben 0.3 Fragrance
0.2B, glycerin 3.0 Propylene glycol
8.0 blended powder
12.0 Urea 3.
OL-ornithine hydrochloride 2.0 purified water
A foundation was obtained according to Example 3, with the total amount being 100.

実施例4に記載された処方よりL−オルニチン塩酸塩の
みを除去した処方を実施例4と同時に調整し、40℃に
て2ケ月保存したのち尿素の定量を行ったところ実施例
4では97〜98%残存していたのに対し、L−オルニ
チン塩酸塩を除去したものは85〜90%に減少してい
た。
A formulation in which only L-ornithine hydrochloride was removed from the formulation described in Example 4 was prepared at the same time as Example 4, and after being stored at 40°C for 2 months, urea was quantified. While 98% remained, in the case where L-ornithine hydrochloride was removed, the amount was reduced to 85-90%.

実施例5 エモリエントエツセンス グリセリン             10.0%プロ
ピレングリコール         5.0エチルアル
コール            5.OP、0.E、 
(50)オレイルエーテル     0.5カルボキシ
ビニルポリマー        1.0尿素     
             1.0リジン酢酸塩   
          1・5アルギニン酢酸塩    
       1.5香料             
     適量精製水         全体を100
とする量上記各成分を均一に混合溶解してエモリエント
エツセンスを得た。
Example 5 Emollient Essence Glycerin 10.0% Propylene Glycol 5.0 Ethyl Alcohol 5. OP, 0. E,
(50) Oleyl ether 0.5 carboxyvinyl polymer 1.0 urea
1.0 lysine acetate
1.5 arginine acetate
1.5 fragrance
Appropriate amount of purified water, total 100
An emollient essence was obtained by uniformly mixing and dissolving the above components in the following amounts.

実施例5に記載された処方より塩基性アミノ酸塩のみを
除去した処方を実施例5と同時に調整し、40℃にて2
ケ月保存したのち尿素の定量をおこなったところ、実施
例5では96〜98%残存していたのに対し、塩基性ア
ミノ酸塩を除去したものは83〜85%に減少していた
A formulation in which only the basic amino acid salt was removed from the formulation described in Example 5 was prepared at the same time as Example 5, and the mixture was heated at 40°C for 2 hours.
After being stored for several months, urea was quantified and found that 96-98% remained in Example 5, while it decreased to 83-85% in the product from which the basic amino acid salt was removed.

Claims (1)

【特許請求の範囲】[Claims] 尿素と塩基性アミノ酸塩とを配合することを特徴とする
皮膚外用剤。
An external skin preparation characterized by containing urea and a basic amino acid salt.
JP15258184A 1984-07-23 1984-07-23 Dermal external drug Pending JPS6130509A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP15258184A JPS6130509A (en) 1984-07-23 1984-07-23 Dermal external drug

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP15258184A JPS6130509A (en) 1984-07-23 1984-07-23 Dermal external drug

Publications (1)

Publication Number Publication Date
JPS6130509A true JPS6130509A (en) 1986-02-12

Family

ID=15543591

Family Applications (1)

Application Number Title Priority Date Filing Date
JP15258184A Pending JPS6130509A (en) 1984-07-23 1984-07-23 Dermal external drug

Country Status (1)

Country Link
JP (1) JPS6130509A (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6440411A (en) * 1987-08-05 1989-02-10 Fujisawa Pharmaceutical Co Humectant cream
FR2675692A1 (en) * 1991-04-24 1992-10-30 Oreal ANTI-OXIDANT SYSTEM CONTAINING PYRROLIDONE CARBOXYLATE LYSINE AND / OR ARGININE PYRROLIDONE CARBOXYLATE EITHER BEING ASSOCIATED WITH A PHENOLIC DERIVATIVE AND ITS USE IN COSMETICS.
WO1995015148A1 (en) * 1993-12-02 1995-06-08 Beiersdorf Ag Topical preparations containing l-arginine
EP0852949A3 (en) * 1997-03-31 1999-08-04 Shiseido Company Limited Use of alpha-amino-acids for enhancing desmosomal degradation or stratum corneum desquamation
FR2815872A1 (en) * 2000-10-31 2002-05-03 Sephra Topical use of arginine pyrrolidone-2-carboxylate as dermal pacifier, antiirritant, and antiaging agent
FR2815866A1 (en) * 2000-10-31 2002-05-03 Sephra METHOD AND DERMATOLOGICAL AND / OR COSMETIC COMPOSITION ANTAGONIZING THE ADHESION EFFECT OF CIRCULATING CELLS
JP2002167328A (en) * 2000-11-29 2002-06-11 Toyo Aerosol Ind Co Ltd Composition and aerosol composition for external skin preparation
WO2020251017A1 (en) * 2019-06-14 2020-12-17 ゼリア新薬工業株式会社 Composition for external application

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5550925A (en) * 1978-10-09 1980-04-14 Sakura Kogyo Kk Muffler silencer producing device

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5550925A (en) * 1978-10-09 1980-04-14 Sakura Kogyo Kk Muffler silencer producing device

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6440411A (en) * 1987-08-05 1989-02-10 Fujisawa Pharmaceutical Co Humectant cream
FR2675692A1 (en) * 1991-04-24 1992-10-30 Oreal ANTI-OXIDANT SYSTEM CONTAINING PYRROLIDONE CARBOXYLATE LYSINE AND / OR ARGININE PYRROLIDONE CARBOXYLATE EITHER BEING ASSOCIATED WITH A PHENOLIC DERIVATIVE AND ITS USE IN COSMETICS.
WO1995015148A1 (en) * 1993-12-02 1995-06-08 Beiersdorf Ag Topical preparations containing l-arginine
EP0852949A3 (en) * 1997-03-31 1999-08-04 Shiseido Company Limited Use of alpha-amino-acids for enhancing desmosomal degradation or stratum corneum desquamation
FR2815872A1 (en) * 2000-10-31 2002-05-03 Sephra Topical use of arginine pyrrolidone-2-carboxylate as dermal pacifier, antiirritant, and antiaging agent
FR2815866A1 (en) * 2000-10-31 2002-05-03 Sephra METHOD AND DERMATOLOGICAL AND / OR COSMETIC COMPOSITION ANTAGONIZING THE ADHESION EFFECT OF CIRCULATING CELLS
WO2002036094A3 (en) * 2000-10-31 2002-08-08 Sephra Method and dermatological and/or cosmetic composition for inhibiting the adhesion effect of circulating cells
JP2002167328A (en) * 2000-11-29 2002-06-11 Toyo Aerosol Ind Co Ltd Composition and aerosol composition for external skin preparation
WO2020251017A1 (en) * 2019-06-14 2020-12-17 ゼリア新薬工業株式会社 Composition for external application

Similar Documents

Publication Publication Date Title
JP3609834B2 (en) Skin preparation
JPH1053510A (en) Composition for external use
JPH027287B2 (en)
JPS6130509A (en) Dermal external drug
JP2003286153A (en) Skin care composition
EP1226822B1 (en) Promoter for production of nitric oxide or nitric oxide synthase, and cosmetic or pharmaceutical composition comprising the same
JPH09124878A (en) Gel composition
JP2691662B2 (en) Cosmetics
JPH0853338A (en) Dermal agent for external use
JPH0232006A (en) External preparation for skin
JP3504038B2 (en) Skin emulsified cosmetic
JP3568983B2 (en) Hair restorer
EP0344708B1 (en) Composition for external application to skin
JPH0481567B2 (en)
JP2004067626A (en) External preparation composition
JPH09301852A (en) Gel composition
JP3712673B2 (en) Gel composition and oil-in-water (O / W) type composition
JP2005281197A (en) Parakeratosis inhibitor, pore reducing agent, and skin external preparation
JP2006347954A (en) Antiseptic for external application agent and dermal application composition
JPS6133105A (en) Skin external preparation
JPH0456002B2 (en)
JPH09263510A (en) Emulsified composition
JP2522803B2 (en) Cosmetics
JPH08268866A (en) Dermal preparation for external use
JPS61130204A (en) Skin cosmetic